Marker Therapeutics (NASDAQ: MRKR) +29%; today announced that the Company received notice of a Product Development Research award totaling approximately $13.1 million from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the Company's Phase 2 clinical trial of its lead MultiTAA-specific T cell product MT-401.

Progenity (NASDAQ: PROG) -30%; announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.

Blend Labs (NYSE: BLND) -10%; reported Q2 EPS of $0.00, versus ($0.53) reported last year. Revenue for the quarter came in at $32.1 million, versus $21.92 million reported last year.

Fate Therapeutics (NASDAQ: FATE) -9%; today highlighted positive interim clinical data from the Company’s FT516 and FT596 programs for patients with relapsed / refractory B-cell lymphoma. FT516 is the Company’s universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. The Company’s FT596 program incorporates both the hnCD16 Fc receptor and a chimeric antigen receptor (CAR) targeting CD19, which is designed to enable multi-antigen targeting of tumor cells, as well as an IL-15 receptor fusion (IL-15RF) to enhance NK cell activity and survival.

Ross Stores (NASDAQ: ROST) -4.8%; reported Q2 EPS of $1.39, $0.45 better than the analyst estimate of $0.94. Revenue for the quarter came in at $4.8 billion versus the consensus estimate of $4.48 billion. Ross Stores sees FY2021 EPS of $4.20-$4.38, versus the consensus of $4.35.